Literature DB >> 9375943

The sympathetic nervous system and the renin-angiotensin-aldosterone system in cardiovascular disease.

R J Cody1.   

Abstract

Both the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) have central roles in vascular adaptive processes. Stimulation of the 2 systems has been demonstrated in a range of cardiovascular disorders, including congestive heart failure and hypertension. However, elucidation regarding the interactions of the many factors involved in these 2 systems is lacking. Angiotensin-converting enzyme inhibitors have been used to reveal the contribution of some elements in the RAAS. Until relatively recently, little was known about the specific disturbances of the sympathetic nervous system in cardiovascular disease. Plasma norepinephrine levels, an indicator of sympathetic activity, have limited value because they are affected by various physiologic processes in addition to sympathetic activation. Newer approaches to the assessment of neurohormonal activity include the determination of the power content of heart-rate variability. More specific probes may lead to a better comprehension of neurohormonal physiology in health and disease and underlie future therapeutic advances targeted to prevention and treatment of specific syndromes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9375943     DOI: 10.1016/s0002-9149(97)00832-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Autonomic nervous system activity in normotensive subjects with a family history of hypertension.

Authors:  Jerica Maver; Martin Strucl; Rok Accetto
Journal:  Clin Auton Res       Date:  2004-12       Impact factor: 4.435

Review 2.  Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders.

Authors:  Christine R Culy; Blair Jarvis
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Progress toward genetic tailoring of heart failure therapy.

Authors:  John H Lillvis; David E Lanfear
Journal:  Curr Opin Mol Ther       Date:  2010-06

4.  Serum angiotensin converting enzyme and the obstructive sleep apnea hypopnea syndrome.

Authors:  John Amit Benjamin; Maria Moller; Philip Ebden; Ionah Bartle; Keir E Lewis
Journal:  J Clin Sleep Med       Date:  2008-08-15       Impact factor: 4.062

Review 5.  Genetic prediction of heart failure incidence, prognosis and beta-blocker response.

Authors:  Fabiana Filigheddu
Journal:  Mol Diagn Ther       Date:  2013-08       Impact factor: 4.074

6.  Lack of Effects of Renin-Angiotensin-Aldosterone System Activity and Beta-Adrenoceptor Pathway Polymorphisms on the Response to Bisoprolol in Hypertension.

Authors:  Weiwei Zeng; Tanya T W Chu; Chung Shun Ho; Clara W S Lo; Alan S L Chan; Alice P S Kong; Brian Tomlinson; Sze Wa Chan
Journal:  Front Cardiovasc Med       Date:  2022-04-01

7.  Associations of adiponectin and leptin with brain natriuretic peptide in African Americans: the Jackson Heart Study.

Authors:  Steven R Horbal; Michael E Hall; Paul C Dinh; Abbas Smiley; Solomon K Musani; Jiankang Liu; Herman A Taylor; Ervin R Fox; Aurelian Bidulescu
Journal:  Cardiovasc Endocrinol Metab       Date:  2020-05-15

8.  Sympathoinhibitory effect of sacubitril-valsartan in heart failure with reduced ejection fraction: A pilot study.

Authors:  Kanokwan Bunsawat; Stephen M Ratchford; Jeremy K Alpenglow; Josef Stehlik; Adam S Smith; Russell S Richardson; D Walter Wray
Journal:  Auton Neurosci       Date:  2021-06-24       Impact factor: 2.355

9.  Renal denervation attenuates aldosterone expression and associated cardiovascular pathophysiology in angiotensin II-induced hypertension.

Authors:  Mo-Na Hong; Xiao-Dong Li; Dong-Rui Chen; Cheng-Chao Ruan; Jian-Zhong Xu; Jing Chen; Yong-Jie Wu; Yu Ma; Ding-Liang Zhu; Ping-Jin Gao
Journal:  Oncotarget       Date:  2016-10-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.